

Medtronic

SINUVA™ (mometasone furoate) sinus implant

Office reimbursement guide

Coding and billing

Possible ICD-10-CM codes ¹	Descriptor
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified

HCPCS ²	Billable units	Descriptor
J7402	1 unit for every 10 mcg = 135 billing units	Mometasone furoate sinus implant, (sinuva), 10 micrograms

NDC number	Descriptor
10599000301	SINUVA (mometasone furoate) 1350 mcg

Wholesale acquisition cost (WAC)
\$1474.35

Multiple procedure modifiers do not apply to HCPCS codes.

CPT® codes

Providers should report the CPT code(s) that most accurately describe the services performed in association with placement of a drug-eluting sinus implant.

Disclaimer

Medtronic provides this information for your convenience only. It does not constitute legal advice or a recommendation regarding clinical practice. Information provided is gathered from third-party sources and is subject to change without notice due to frequently changing laws, rules and regulations. The provider has the responsibility to determine medical necessity and to submit appropriate codes and charges for the care provided. Medtronic makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other payers as to the correct form of billing or the amount that will be paid to providers of service. Please contact your Medicare contractor, other payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage and payment policies. This document provides assistance for FDA approved or cleared indications. Where reimbursement is sought for use of a product that may be inconsistent with, or not expressly specified in, the FDA cleared or approved labeling (e.g. instructions for use, operator's manual or package insert), consult with your billing advisors or payers on handling such billing issues. Some payers may have policies that make it inappropriate to submit claims for such items or related service.

INDICATION

SINUVA™ (mometasone furoate) sinus implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA sinus implant should not use SINUVA implants.

Please see additional important safety information on the next page.

Physician office billing

A	21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY. Relate A-L to service line below (24E)										ICD-10-CM		22. RESUBMISSION CODE		ORIGINAL REF. NO.																
	A. XXX.X		B. _____		C. _____		D. _____		E. _____		F. _____		G. _____		H. _____																
B	24. A. DATE(S) OF SERVICE										B. PLACE OF SERVICE		C. EMG		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS		E. DIAGNOSIS POINTER		F. \$ CHARGES		G. DAYS OR UNITS		H. EPSDT Family Plan		I. ID. QUAL.		J. RENDERING PROVIDER ID. #				
	MM		DD		YY		MM		DD		YY		SERVICE		EMG		CPT/HCPCS		MODIFIER		DIAGNOSIS POINTER		\$ CHARGES		DAYS OR UNITS		EPSDT Family Plan		ID. QUAL.		RENDERING PROVIDER ID. #
23. PRIOR AUTHORIZATION NUMBER																															
N410599000301 UN2																															
1		04		01		21						11		C J7402						F A		D XXX				NPI					
2		04		01		21						11		E XXXXX						F A		01				NPI					

A. Item 21A report ICD-10-CM diagnosis code.

B. Shaded area of box 24, add the following:
N4 qualifier, 11-digit NDC code (insert one space) and UN followed by the quantity. UN1 is inserted for SINUVA™ (mometasone furoate) sinus implant unilateral procedures and UN2 is used for bilateral procedures

Please note: Payer NDC requirements and placement may vary. Check with payer.

C. Item 24D report HCPCS code J7402 for Sinuva.

D. If reporting unilateral/1 unit of SINUVA implant, input 135 units.
If reporting bilateral/2 units of SINUVA implant, input 270 units.

E. Item 24D report applicable CPT procedure code.

F. Item 24E indicate A to associate SINUVA implant with diagnosis code entered in item 21A above.

CPT copyright 2021 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Important safety information (continued)

WARNINGS AND PRECAUTIONS

Local Effects: Monitor nasal mucosa adjacent to the SINUVA sinus implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

Please see additional important safety information on the next page.

Billing the National Drug Code (NDC)

When billing physician administered drugs with a J Code, payers may require the 11-digit NDC to be included on claims. The 11-digit billable NDC for SINUVA™ (mometasone furoate) sinus implant is **10599000301**.

For proper claim filing this information must be captured in a specific format as shown below.

Electronic claims (ANSI 5010 837)		Loop	Segment
Product ID qualifier	Enter N4 in this field	2410	LIN02
National Drug Code	Enter 11-digit NDC 10599000301	2410	LIN03
National Drug Code unit count	Enter quantity (number of NDC units) 1 (unilateral) or 2 (bilateral)	2410	LIN04
Unit of measure	Enter NDC unit of measure as UN followed by units billed 1 unit = UN1	2410	CTP05

Obtaining SINUVA™ (mometasone furoate) sinus implant

To order SINUVA implant for in-office use, please call the Specialty Distributor Besse Medical at **1-800-543-2111** or McKesson Med Surg at **1-855-571-2100**.

Important safety information (continued)

Warnings and precautions (continued)

Ocular Effects: Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely.

Please see additional important safety information on the next page.

Important safety information (continued)

Warnings and precautions (continued)

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

Immunosuppression: Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

Hypercorticism and Adrenal Suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

ADVERSE REACTIONS

The most common adverse reactions observed (> 1% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

POSTMARKETING EXPERIENCE

The following adverse reactions have been identified during post-approval use of the SINUVA sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.

Rx only. Please see attached Full Prescribing Information for SINUVA sinus implant and at SINUVA.com/PI.

References

1. Centers for Disease Control and Prevention, National Center for Health Statistics. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). <https://www.cdc.gov/nchs/icd/icd10cm.htm>. Accessed November 16, 2021.
2. Healthcare Common Procedure Coding System (HCPCS) Level II codes, including device C-codes, are maintained by the Centers for Medicare and Medicaid Services. <http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html>. Accessed November 16, 2021.

Medtronic

ENT

6743 Southpoint Drive N
Jacksonville, FL 32216
USA
Toll free: 800-874-5797
Telephone: 904-296-9600
Fax: 800-678-3995